19 May 2013
Keywords: Nektar Thera, Royalty Pharma, UCB, Roche, Cimzia, Mircera, Rheumatoid arthritis, Anemia
Article | 01 March 2012
US biotech firm Nektar Therapeutics (Nasdaq: NKTR) has agreed to sell to Royalty Pharma its royalties on future sales of ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
1 March 2012
28 February 2012
6 March 2012
17 May 2013
© 2013 thepharmaletter.com